The american journal of psychiatry publishes data demonstrating akili interactive's digital therapeutic akl-t03 improves cognitive impairments in adults with major depressive disorder when combined with antidepressant medication

Boston--(business wire)--akili interactive (“akili”), a leading cognitive medicine company improving health through game-changing technologies, today announced that the american journal of psychiatry has published findings from the stars-mdd clinical trial evaluating akili's akl-t03 digital therapeutic as a potential treatment for attention impairments in adults with major depressive disorder (mdd) when used alongside antidepressant medication. more than 16 million people in the united states a
AKLI Ratings Summary
AKLI Quant Ranking